Status:
COMPLETED
A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation
Lead Sponsor:
The Prince Charles Hospital
Collaborating Sponsors:
Cell and Tissue Therapies Western Australia
Conditions:
Bronchiolitis Obliterans
Lung Transplantation
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
The primary aim of this study is to establish the safety of infusions of Mesenchymal Stromal Cells (MSC) from related or unrelated Human Leukocyte Antigen (HLA) identical or HLA mismatched donors in t...
Eligibility Criteria
Inclusion
- Patients with single, bilateral or heart-lung allografts
- Patients with bronchiolitis obliterans syndrome (BOS) grades 2 \& 3 (defined and graded according to international criteria (Appendix 1)), with evidence of deterioration in allograft function (i.e. deteriorating FEV1 or worsening BOS grade) within the last 12 months.
- Patients with BOS grade 1 and evidence of deterioration in allograft function (i.e. deteriorating FEV1 or worsening BOS grade) within the last 12 months and at least one of the following additional risk factors for subsequent death:
- Single lung transplant
- Rapid deterioration (\>20% fall in FEV1 in the previous 12 months)
- A pre-transplant diagnosis of usual interstitial pneumonia (pulmonary fibrosis) or pulmonary hypertension
Exclusion
- Patients with active infection, acute allograft rejection, or airway anastomotic complications
- Patients with \> 3 infective exacerbations of BOS in the last 12 months
- Patients with a history of cytomegalovirus (CMV) pneumonitis
- Patients with poor performance status and/or not expected to survive 3 months
- Patients who are pregnant or breastfeeding
- Patients with an allergy to beef products.
- Any condition that in the opinion of the Investigator may interfere with the safety of the patient, his / her completion of required follow-up visits or evaluation of the study objectives.
Key Trial Info
Start Date :
February 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01175655
Start Date
February 1 2010
End Date
July 1 2016
Last Update
April 26 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
TPCH
Brisbane, Queensland, Australia, 4032
2
RPH
Perth, Western Australia, Australia, 6000